Variations in the cerebellum to plasma ratio at late times in 6-['8Fjfluoro-L-DOPA studies are shown to be con sistent with competitive binding of large neutral amino acids for a common transporter in the blood-brain barrier and the stability of brain tissue large neutral amino acid level in the presence of plasma level changes. The distribution volume of an inert large neutral amino acid can be estimated from plasma and tissue large neutral amino acid levels and apparent half-
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We have recently reported (Stout et aI., 1998 ) that for 6-[ 1 8 Flfluoro-L-DOPA (FDOPA), both the forward transport constant (K 1 ) across the blood-brain barrier (BBB) and the ratio of cerebellar to plasma radioactivity concentrations at late times (i.e., 120 minutes after tracer injection) in vervet monkeys are functions of the plasma level of large neutral amino acids (LNAA). Specifically, both quantities decrease as plasma LNAA concentration increases. In more recent FDOP A work in squirrel mon keys, similar findings were observed (unpublished data). The finding of decreased K I is not surprising because it is known that LNAA are transported across the BBB through a carrier-mediated transport system that is satu rable (Oldendorf, 1971; Pardridge, 1977) . Higher plasma saturation concentrations (Km) of the transporter in the blood brain barrier. Stability of brain large neutral amino acid levels is supported by literature findings and can be explained by high saturation of the large neutral amino acid transporter at physi ologic conditions. Key Words: Large neutral amino acid Blood-brain barrier-LNAA transport carrier-Tissue LNAA concentration-6-[ 18Flfluoro-L-DOP A.
LNAA concentrations would increase the competition for the carrier. However, the decreased ratio of cerebellar to plasma radioactivities versus plasma LNAA concen tration is somewhat unexpected. Because at 120 minutes after FDOP A injection, plasma and cerebellar radioac tivity is mostly peripherally borne 3-0-methyl-6r I 8 Flfluoro-L-DOPA (OMFD) (85% ± 3% in vervets and 95% ± 2% in squirrels), the measured ratio of cerebellar to plasma radioactivity at 120 minutes represents mainly the distribution volume of OMFD in the cerebellum. In ferred from the facts that (1) OMFD is inert in brain tissue (i.e., not involved in biochemical processes in the brain), (2) OMFD is present in trace amounts, and (3) the aqueous tissue space that OMFD dissolves in is not changed, one would have expected that OMFD should have a constant distribution volume, characterized only by its biochemical properties in tissue.
In this communication, we reexamine the theory of LNAA transport across the BBB. The theory leads to a logical explanation of the observed distribution volume changes that is consistent with literature findings on plasma and brain LNAA levels in rats. Implications on improved FDOP A quantitation, in vivo tissue LNAA measurements, and L-DOPA therapy (in Parkinson's dis ease) will also be addressed.
THEORY OF LNAA TRANSPORT ACROSS THE

BLOOD-BRAIN BARRIER
Because the same LNAA transport carriers are shared by all LNAA for their transport across the BBB (Olden dorf, 1971; Pardridge, 1977) , changes in the concentra tion of any one LNAA would affect the transport rate of others. Based on the Michaelis-Menten equation for competitive enzyme binding or carrier transport, the in flux (in units of nmol'min-1'g-l) of a particular LNAAj across the BBB can be formulated (Pardridge, 1977; Miller et aI., 1985; Segel, 1975) as (1) where [AA]F is the plasma concentration (in nmol/mL) of LNAAj; Vmj and Kmj are respectively the maximal rate (in nmol'min-1'g-l) and half-saturation concentra tion (in nmol/mL) of LNAAj for the transport carrier. The summation term in the denominator sums over all LNAA (index k) in plasma. Kmk and [AA]k denote re spectively the half-saturation concentration and the plasma concentration of LNAAk• Similarly, by assuming that LNAA in tissue can be approximated as a single compartment (i.e., a pool of uniform LNAA concentra tion), the outflux (in nmol'min-1 'g-l) of LNAAj is Vm./Km (2) which is identical in form to the influx (Eq. I), except that the plasma LNAA concentrations are replaced by the tissue concentrations ([AA]: and [AA]�, in nmol/g). In
Eqs. 1 and 2, Vm and Km are assumed to have the same values between the inward and outward transports of each LNAA, except that the units are different (i.e., the unit of Km for influx is nmol/mL and for outflux is nmol/g).
The transport constants for the inward and outward transport of LNAAj can thus be described by If LNAAj is not involved in biochemical processes within the tissue (as is the case for OMFD), the influx and outflux at equilibrium should be equal, and the dis tribution volume of LNAAj in tissue can be related to total LNAA concentrations as where and
denote, respectively, the apparent Km for total tissue and plasma LNAA transport across the BBB; [LNAA]P and [LNAAr are the total LNAA concentrations in plasma and tissue, respectively; fk and ft are, respectively, the fractions (with respect to total LNAA) of LNAAk in plasma and tissue. Moreover, if LNAAj is in trace amounts (i.e., [AA]F and [AA]: are small), the summa tion terms in the above equations do not need to include the term caused by LNAAj• Therefore, the distribution volume of an inert LNAA in trace amounts (e.g., a ra diolabeled inert LNAA) will depend only on the concen tration to Km ratios of other LNAA (in tissue and in plasma) (Eq.6). According to Eq. 7, the distribution vol ume of such an LNAA will be changed only when the total LNAA concentration in plasma is changed relative to that in tissue, or when the relative concentrations of LNAA in plasma or in tissue (i.e.,jk andfD are changed such that they alter the apparent Km (Km�pp and Km�pp).
In other words, one needs to know the LNAA concen trations in plasma and in brain tissue as well as the ap parent Km values to predict the distribution volume of an inert radiolabe1ed LNAA.
If a radiolabeled LNAA is not inert and is involved in tissue biochemical reactions (e.g., protein synthesis), its distribution volume will not be determined by Eqs. 5-7 above. For example, the distribution volume of [ 11 C]L_ leucine is not expected to be equal to the value based on Eq. 7. Furthermore, the distribution volume of [I I C]L_ leucine is not expected to be equal to the ratio of tissue leucine concentration to plasma leucine concentration ei ther, because tissue leucine level is influenced also by its endogenous supply of amino acids from protein degra dation.
In the above derivation, the values of Km and Vm were assumed to have the same values between the inward and outward transport. If the values were different, the gen eral relationship of Eq. 7 will still hold except that a scaling factor, dependent on the specific LNAAj, may need to be introduced. Also, a single transport system is assumed in the above discussion. Although it appears that more than one system may exist for LNAA across the BBB (e.g., the high-and low-affinity systems dis cussed by Hargreaves and Pardridge, 1988) , transport is normally dominated by one system.
PLASMA AND BRAIN
LNAA CONCENTRATIONS
Many investigators have previously measured plasma and brain LNAA concentrations in rats. In at least three investigations, plasma and brain LNAA concentrations were measured for the same sets of animals in the same experiment. In a study by Glanville and Anderson (1985) , four groups of normal animals (n = 6, 5, 6, and 5) were fed with diets of different protein contents (15%, 30%, 45%, and 60%) for 2 weeks. Plasma and whole brain concentrations of eight LNAA were then deter mined and reported in graphs. The values taken from the graphs are listed in Table 1 . In a study by Meloche and Smith (1995) to evaluate the effect of T-2 toxin on amino acid metabolism, two sets of control studies (n = 10 for each set) were performed, and the plasma and brain con-centrations of seven LNAA were measured. Their re ported values are also listed in Table 1 . Voog and Eriks son (1992) measured the plasma and brain concentra tions of six LNAA (without methionine) in three groups of rats (n = 7 per group) at 2 hours after a meal of 0%, 18%, and 40% protein for the three groups (animals had been fasted for 12 hours and had been on 16% protein for 2 weeks before fasting). Their measured values are listed in Table 1 .
Although there are variations among determinations as well as methodological differences, it is clear from these literature findings that the total LNAA levels in brain tissue are mostly lower than those in plasma. Moreover, plasma LNAA concentrations can change significantly with various interventions, but only relatively small ef fects appear on brain tissue LNAA concentrations.
AGREEMENT BETWEEN MEASURED AND CALCULATED DISTRIBUTION VOLUMES
Based on the plasma and brain LNAA concentrations listed in Table 1 and by using the Km values reported by Miller et al. (1985) for various LNAA, the distribution volume of an inert LNAA in trace amounts can be cal culated with Eq. 7. Although not all LNAA concentra tions are available (missing values were considered zero in the calculation), the LNAA with large Km contribute little to the summation terms in Eqs. 8 and 9 and thus will not affect significantly the apparent Km values (i.e., Km� pp and Km� pp ) and the calculated Yd' The calculated
Vd for different sets of LNAA measurements are listed in Table 1 and shown in Fig. 1 as a function of total plasma LNAA level. Also shown in the figure are cerebellum to plasma radioactivity ratios measured in vervet monkeys with FDOPA (Stout et aI., 1998 1985) ; open squares were from data of Meloche and Smith (1995) ; triangles were based on LNAA data of Voog and Eriksson (1992) .
have also been reported for anesthetized animals (Smith et aI., 1987) and for isolated capillary preparations (Har greaves and Pardridge, 1988 
MECHANISMS ACCOUNTABLE FOR THE APPARENT LACK OF EQUILIBRIUM
The relative constancy of tissue LNAA, in spite of a large variation in plasma concentration (Table 1; Glan ville and Anderson, 1985; Voog and Eriksson, 1992) , could appear as a lack of equilibrium of LNAA across the BBB. The existence of active cellular processes that could offset the concentration gradients was proposed (Glanville and Anderson, 1985) . These authors sug gested that "an alteration either in transport mechanisms or in brain metabolism occurs" to explain the tissue LNAA's "relative resistance to change." However, a simpler explanation can be offered, involving the high level of saturation of the transport carrier system. In fact, transport saturation and competition as a means to main tain homeostasis of brain LNAA has been proposed be fore by Smith et al. (1987) . As shown in Table 1 , the LNAA levels in plasma and in tissue are mostly larger than the Km values of the corresponding LNAA. Based on the competitive carrier kinetics discussed earlier, the fraction of total carrier occupied by any LNAAk (jrk) can be calculated by the following equation (Segel, 1975) .
And the fraction that is not occupied (jr f ree) is (11) Based on the values listed in Table 1 , (jr f ree) is calculated to be less than 0.04 to 0.08. In other words, the transport carrier is working at close to its maximal transport ca pacity. So, as the plasma LNAA is increased or de creased, the influx of LNAA would show little change and thus would not affect significantly the tissue amino acid level.
In fact, under normal conditions, the outward transport is also highly saturated, and changes in the tissue LNAA level are not expected to change the outflux much. Therefore, in effect, brain tissue can establish an amino acid environment that is suitable for its biologic function, but insulated from large plasma fluctuations caused by dietary intake and peripheral systemic control (Voog and Eriksson, 1992; Glanville and Anderson, 1985) . How ever, if the relative fractions of LNAA in plasma are significantly altered (as in pathologic conditions), tissue LNAA homeostasis is not expected to be maintained.
From Eq. 7, the distribution volume of an inert LN AA, such as OMFD in brain and FDOP A in the cerebellum, is related to both plasma and tissue total LNAA concentra tions and to the apparent Km values. In Table 1 , the apparent Km values for all sets of LNAA concentrations are also listed. The values are quite stable (Km�pp = 87.0 ± 9.8 mmoliL and Km�pp = 81.6 ± 6. 3 nmol/g). Because
Vd of OMFD can be easily measured in vivo with PET, and total plasma LNAA concentration can be assayed from blood samples, total tissue LNAA concentration can be determined with Eq. 7. For example, the value of Vd is about 0.7 mLig for a plasma LNAA concentration of 500 mmoliL (Stout et aI., 1998;  Fig. 1 ). Using Eq. 7, 87.0 mmollL for Km�pp, and 81.6 nmol/g for Km�pp, the total brain LNAA concentration in vervet monkeys can be calculated to be 304 nmol/g, or [(500/87.0 + 1) x 0.7 -1] x 81.6. From the relatively constant value of the apparent Km shown in Table I , the calculated tissue LNAA value should have small variability. Nevertheless, variation from an assumed distribution spectrum is ex pected to affect somewhat the accuracy of the determi nation. For the cerebellum or other brain tissues, in which FDOPA is not decarboxylated or biochemically trapped, the tissue LNAA concentration can be measured with FDOPA (Stout et aI., 1998) . Further investigation and validation of this approach are ongoing in our labo ratory.
IMPROVED QUANTITATION OF
FDOPA KINETICS
With the better understanding of the distribution vol ume of LNAA provided in this communication, one can improve the modeling and quantitation of the measured FDOP A kinetics. For example, instead of using a fixed Vd value for OMFD in the modeling of striatal kinetics, one can use the value determined from the cerebellum. This is expected to improve the reliability of the mea surements. We have observed previously in our labora tory that in the calculation of the striatal uptake constant (K) of FDOP A, the use of cerebellum as a kinetic ref erence region (i.e., by subtracting the cerebellar activity from the striatal activity curve and applying Patlak J Cereb Blood Flow Metab, Vol. 18, No. 12, 1998 analysis; Patlak et ai . , 1983) gives a result of smaller variability than the value estimated from fitting the stria tal kinetics with an FDOPA model that assumes a fixed Vd value of 1.0 mLig for OMFD (Huang et aI., 1991) . The model-fitting approach estimated the tissue OMFD kinetics from plasma OMFD curve, on the basis of the assumed value of Vd• Preliminary data show that an over estimation of the Vd value by 0.3 mLig (corresponding to a total plasma LNAA of about 500 nmol/mL) in the model fitting could lower the calculated striatal Kj value by 21 % to 37% in vervet monkeys. If the measured cer ebellum to plasma ratio (at 120 minutes) is used as the value of Vd, the Kj results from model fitting are found to have reduced variability and correlate well with those obtained with the Patlak analysis (i.e., the approach that first subtracts the cerebellar activity from the striatal ki netics) (unpublished data).
Results by FDOP A quantitation methods that use the cerebellar curve as the input function are not expected to be affected much by the distribution volume variation (because plasma LNAA affects K J [of FDOPA] and Vd similarly), although they might be sensitive to other fac tors, such as the O-methylation activity in the periphery, which can influence plasma and tissue OMFD levels. The use of cerebellar Vd value (either directly measured or estimated from plasma LNAA level) in the FDOPA model fitting is expected to improve the reliability of other model parameters (e.g., k2 and k3) as well. This investigation is currently ongoing in our laboratory.
MULTIPLE TRANSPORT BARRIERS IN TISSUE
The discussion so far considers the tissue as a homo geneous compartment of amino acids. However, there is evidence in the literature indicating that the transport of LNAA across the neuronal membrane is also mediated by a carrier system (Aragon et aI., 1982; Katz, 1980; Kapatos and Zigmond, 1977; Barrio et aI., 1997) . Al though not much information about this transport system is available now, it is conceivable that this transport is also saturated under normal conditions. Following the same argument for the transport across the capillary, it is likely that cellular and interstitial concentrations of LNAA can be different. In fact, without the need of a sophisticated system, different cells could maintain dif ferent LNAA concentrations that are most suitable for the functional states of the individual cells.
IMPLICATION FOR L-DOPA TREATMENT OF
PATIENTS WITH PARKINSON'S DISEASE
The saturation of the LNAA carrier system in the BBB also has intriguing implications in drug therapy, specifi cally the use of L-DOPA for the treatment of patients with Parkinson's disease. Administration of large doses of L-DOPA would elevate its plasma level and would allo w it to compete against other LNAA for its transport across the BBB. This will reduce the inward transport of other LNAA into the brain. However, after the L-DOPA is transported into tissue, if it is largely decarboxylated to form dopamine, tissue L-DOPA will not compete for outward LNAA transport. Based on a plasma L-DOPA concentration that fluctuates between I and 10 mmol/L in patients on L-DOPA treatment (Nutt and Woodward, 1986 ) and a forward transport constant of 0.03 mL'min-t 'g-t (Huang et aI., 1991) , the peak L-DOPA influx is 0.30 nmol·min-t . g-t , which is less than the normal dopamine synthesis rate of 0. 33 nmol'min -t 'g -t (Doteuchi et aI., 1974) . Therefore, L-DOPA decarboxyl ation is capable of consuming all the influx L-DOPA in the striatum if the endogenous supply is severely dimin ished. As a result, LNAA influx is reduced by L-DOPA competition without a concordant reduction in outflux, and the striatal tissue may experience a net loss of LNAA (assuming the influx and outflux were in equilibrium before the introduction of L-DOPA). Although the mag nitude of the imbalance is small (estimated to be about 1% of the total LNAA influx; Eq. 10), patients with Parkinson's disease are usually treated for years with L-DOPA, and, with time, the striatal tissue may experi ence reduced LNAA levels (unless certain adaptation exists in the brain, such as the upregulation of transporter expression). Even though many other logical explana tions have been suggested before to account for the gradually reduced efficacy of L-DOPA treatment in pa tients with Parkinson's disease, the possible linkage war rants a careful in-depth examination of these issues in patients, as well as additional experiments in animals.
